No Data
No Data
No Data
No Data
No Data
Advaxis and Ayala Pharmaceuticals Complete Merger
REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and com
GlobeNewswireJan 19, 2023 09:41 ET
Advaxis, Inc. (OTCMKTS:ADXS) Sees Significant Decline in Short Interest
Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) was the target of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 2,400 shares
Defense WorldDec 5, 2022 02:31 ET
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Advaxis, Inc. (ADXS)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - October 19, 2022) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Advaxis, Inc. (
newsfileOct 19, 2022 14:55 ET
Short Interest in Advaxis, Inc. (OTCMKTS:ADXS) Drops By 27.5%
Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) was the target of a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 2,900 shares, a dro
kopsourceOct 1, 2022 12:22 ET
Advaxis, Inc. (OTCMKTS:ADXS) Short Interest Down 27.5% in September
Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) saw a large decrease in short interest in September. As of September 15th, there was short interest totalling 2,900 shares, a decrease of 27.5% from the Aug
Defense WorldSep 30, 2022 02:11 ET
Advaxis Reports Third Quarter Ended July 31, 2022 Financial Results and Provides a Business Update
Announced completion of first dose level and enrollment initiation for second dose level in investigator-sponsored study of ADXS-504 in biochemically recurrent prostate cancer Cash runway extends into
GlobeNewswireSep 12, 2022 18:45 ET
No Data
No Data